NKGen Biotech (NKGN) Competitors $0.0010 +0.00 (+66.67%) As of 12:53 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NKGN vs. FNCH, LEXX, PRPH, NAII, CLRB, EDSA, THAR, NRSN, AYTU, and PULMShould you be buying NKGen Biotech stock or one of its competitors? The main competitors of NKGen Biotech include Finch Therapeutics Group (FNCH), Lexaria Bioscience (LEXX), ProPhase Labs (PRPH), Natural Alternatives International (NAII), Cellectar Biosciences (CLRB), Edesa Biotech (EDSA), Tharimmune (THAR), NeuroSense Therapeutics (NRSN), Aytu BioPharma (AYTU), and Pulmatrix (PULM). These companies are all part of the "pharmaceutical products" industry. NKGen Biotech vs. Its Competitors Finch Therapeutics Group Lexaria Bioscience ProPhase Labs Natural Alternatives International Cellectar Biosciences Edesa Biotech Tharimmune NeuroSense Therapeutics Aytu BioPharma Pulmatrix Finch Therapeutics Group (NASDAQ:FNCH) and NKGen Biotech (NYSE:NKGN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership. Is FNCH or NKGN more profitable? NKGen Biotech's return on equity of 0.00% beat Finch Therapeutics Group's return on equity.Company Net Margins Return on Equity Return on Assets Finch Therapeutics GroupN/A -69.14% -26.92% NKGen Biotech N/A N/A -479.36% Does the media favor FNCH or NKGN? In the previous week, NKGen Biotech had 1 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 2 mentions for NKGen Biotech and 1 mentions for Finch Therapeutics Group. Finch Therapeutics Group's average media sentiment score of 0.00 equaled NKGen Biotech'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Finch Therapeutics Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NKGen Biotech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, FNCH or NKGN? Finch Therapeutics Group has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500. Comparatively, NKGen Biotech has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500. Do institutionals & insiders hold more shares of FNCH or NKGN? 21.8% of Finch Therapeutics Group shares are owned by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are owned by institutional investors. 44.9% of Finch Therapeutics Group shares are owned by insiders. Comparatively, 10.4% of NKGen Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has better valuation & earnings, FNCH or NKGN? Finch Therapeutics Group is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFinch Therapeutics GroupN/AN/A-$74.75M-$8.82-1.38NKGen BiotechN/AN/A-$82.94M-$2.450.00 SummaryNKGen Biotech beats Finch Therapeutics Group on 5 of the 9 factors compared between the two stocks. Get NKGen Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for NKGN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NKGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NKGN vs. The Competition Export to ExcelMetricNKGen BiotechBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$45K$357.69M$6.14B$22.09BDividend YieldN/AN/A5.66%3.59%P/E Ratio0.00N/A85.8429.58Price / SalesN/A480.89626.3664.95Price / CashN/A22.4438.3224.53Price / Book0.003.9013.064.61Net Income-$82.94M-$133.30M$3.30B$1.01B7 Day PerformanceN/A3.11%4.81%-0.46%1 Month PerformanceN/A18.10%9.99%2.30%1 Year PerformanceN/A23.82%85.28%14.51% NKGen Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NKGNNKGen Biotech0.1455 of 5 stars$0.00+66.7%N/A-99.8%$45KN/A0.00N/ANews CoverageGap UpFNCHFinch Therapeutics Group0.7706 of 5 stars$12.28+0.2%N/A+5.2%$19.72MN/A-1.39190LEXXLexaria Bioscience2.8903 of 5 stars$0.95-3.1%$4.00+319.9%-70.3%$19.22M$460K-1.427News CoverageAnalyst ForecastPRPHProPhase Labs0.4041 of 5 stars$0.46+4.6%N/A-77.8%$18.19M$6.77M-0.36130Analyst ForecastGap UpNAIINatural Alternatives International1.3159 of 5 stars$2.84-2.6%N/A-40.2%$17.97M$129.86M-1.25290Analyst ForecastCLRBCellectar Biosciences2.399 of 5 stars$5.60+3.5%$375.00+6,596.4%-92.5%$17.27MN/A-0.2810Analyst ForecastEDSAEdesa Biotech3.2524 of 5 stars$2.47+0.8%$5.00+102.4%-36.2%$17.24MN/A-1.8720Positive NewsAnalyst ForecastHigh Trading VolumeTHARTharimmune2.5079 of 5 stars$2.84-2.1%$17.00+498.6%+56.7%$17.12MN/A-0.472News CoverageAnalyst ForecastNRSNNeuroSense Therapeutics2.3306 of 5 stars$1.25flat$14.00+1,020.0%+0.0%$17.08MN/A-2.3110News CoveragePositive NewsAnalyst ForecastAYTUAytu BioPharma3.7914 of 5 stars$1.88+9.9%$9.17+387.6%+0.9%$16.95M$66.38M-0.67160PULMPulmatrix0.9892 of 5 stars$4.86+6.6%N/A+138.2%$16.64M$369K-2.2420Positive NewsAnalyst Forecast Related Companies and Tools Related Companies Finch Therapeutics Group Alternatives Lexaria Bioscience Alternatives ProPhase Labs Alternatives Natural Alternatives International Alternatives Cellectar Biosciences Alternatives Edesa Biotech Alternatives Tharimmune Alternatives NeuroSense Therapeutics Alternatives Aytu BioPharma Alternatives Pulmatrix Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:NKGN) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NKGen Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NKGen Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
